October 29, 2024

Immorta Bio's SenoVax™ Reduces Growth and Stops Metastasis of Aggressive Breast Cancer Using its First-In-Class Immune Stimulatory Therapy

SenoVax  “Teaches” Immune System to Remove Protective Shield Around Tumors

Immorta Bio Inc., a scientific longevity company focused on "Treating Diseases of Aging and Treating Aging as Disease™," announced today the successful treatment of aggressive breast cancer in animal models using its SenoVax™ senolytic immunotherapy.  In a series of experiments, scientists at Immorta Bio found that the administration of SenoVax resulted in the shrinkage of existing breast cancers and reduced metastasis.  

SenoVax was previously demonstrated to reduce lung cancer growth[1], which was the subject of the Company’s IND #30745[2]. It has also been shown to accelerate the recovery of blood cell production after chemotherapy [3].

“The currently disclosed data, which is covered by several filed patents, is extremely promising and potentially will offer one more weapon in our fight against triple-negative metastatic breast cancer.”  Said Dr. Thomas E. Ichim, President and Chief Scientific Officer of Immorta Bio. “Very intriguing is that mice which received SenoVax had an increase in several immunological parameters suggesting that besides cancer suppression, the therapy actually had a “regenerative” effect.”

“I am thankful to our team of scientists and collaborators who are working at a breakneck pace to apply lessons learned from our work in longevity to chronic health conditions such as cancer.” Said Dr. Boris N Reznik, Chairman and CEO of Immorta Bio. “To our knowledge, SenoVax is the first immunotherapy that works by removing senescent cells that surround the tumor.  Once these are removed, the body does what it does best: defend itself.”

About Immorta Bio
Immorta Bio Inc. is a scientific longevity company developing personalized cellular therapeutics focused on "Treating Diseases of Aging and Treating Aging as Disease™." We are advancing longevity medicine by harnessing patient-derived rejuvenated stem cells and enhanced immune cells, restoring your body's natural ability to combat cancers and age-related diseases. Our mission is to address the root causes of aging and bring resilience and vitality back to you.

For more information, please visit the Immorta Bio website at https://www.immortabio.com or

X

Linkedin

Company Contact
Dr. Boris Reznik
Immorta Bio
https://www.immortabio.com 
+1 305-632-2939 

[1] https://www.biospace.com/immorta-bio-reports-successful-inhibition-of-lung-cancer-growth-by-senolytic-immunotherapy-product-senovax

[2] https://www.targetedonc.com/view/senovax-investigational-new-drug-application-filed-with-the-fda-in-nsclc

[3] https://www.prnewswire.com/news-releases/senovax-breakthrough-cancer-immunotherapy-preserves-immune-function-post-chemotherapy-in-animal-models-302239460.html

Explore More

November 20, 2024

Nature Publication Supports Senolytic Approach for Cancer Treatment

November 3, 2024

Immorta CSO Featured in BioFuture 2024 Longevity Panel

October 21, 2024

Featured on The Bio Report Podcast - Targeting Senescent Cells

See all news
Join our newsletter to stay up to date on features and releases
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By subscribing, you are acknowledging your consent to receive  Immorta Bio newsletters
19505 Biscayne Blvd, Ste 2350 Aventura, Florida 33180
305 632-2939
info@immortabio.com